Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

patient experience

How Patient Advocacy Can Positively Disrupt Healthcare

Seth Rotberg, Patient Recruitment Manager at WEGO Health & Co-Founder of Our Odyssey, shares his views on how to empower rare disease patients, improve clinical trials, and move towards a...

Impetus Digital

Leaders in Pharma: Danielle Portnik

In this episode of Impetus Digital's Leaders in Pharma podcast, I sit down with Danielle Portnik. She is currently the Regional Business Director for International with Ambry Genetics.

Impetus Digital

- PMLiVE

FDA removes clinical hold on uniQure’s haemophilia gene therapy

Clinical hold placed following a case of hepatocellular carcinoma in a patient in the trial

- PMLiVE

bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021

Previously reported case of MDS in phase 1/2 study has been re-classified as transfusion-dependent anaemia

Advancing Precision Medicine in Oncology

Jerome Madison, Host of The Precision Medicine Podcast, shares his leadership lessons and tips for building and training new sales teams in the era of precision medicine. He also dives...

Impetus Digital

- PMLiVE

Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline

Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology

- PMLiVE

Novartis bolsters radioligand therapy pipeline with new licence agreement

Radioligand therapies are a new potential class of precision oncology drugs

- PMLiVE

Unpacking rare diseases in the first edition of Delta magazine

Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization.

Avalere Health

- PMLiVE

bluebird bio reveals long-term data for Lenti-D gene therapy in CALD

At 24 months of follow-up, 90% of patients were free of major functional disabilities

Alternative Approaches to Personalized Medicine in Oncology

Laura Towart, Founder & CEO of My Personal Therapeutics, discusses her company’s approach to precision medicine, the barriers patients with cancer face when trying to access personalized treatments, and how...

Impetus Digital

- PMLiVE

bluebird bio says AML case “very unlikely” to be related to gene therapy LentiGlobin

bluebird bio's gene therapy LentiGlobin is used to treat sickle cell disease

Gene Editing and Precision Medicine: The Future of Healthcare?

Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links